Key Points
[1/2]U.S. Senator Elizabeth Warren (D-MA) faces reporters during a break in a bipartisan Artificial Intelligence (AI) Insight Forum for all U.S. senators at the U.S. Capitol in Washington, U.S., September 13, 2023..
WASHINGTON, Nov 9 (Reuters) - Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen (AMGN.O) to move forward with its acquisition of Horizon Therapeutics...
Warren, a Democrat, has staunchly supported the FTC and Justice Department's tougher stance on mergers under President Joe Biden..
The settlement involved requirements that Amgen refrain from bundling any of its products with two Horizon medicines: Tepezza, which treats thyroid eye disease, or a medicine for chronic gout called Krystexxa.. Warren said that she was concerned that these and other behavioral remedies were "difficult to administer and enforce and cease to be binding once the term of the agreement ends, though anticompetitive effects remain.".
You might be interested in
Amgen gets US FTC's go-ahead for $27.8-bn Horizon deal
01, Sep, 23The agreement, announced on Friday, ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.
Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle
01, Sep, 23Agreement with Federal Trade Commission allows transaction to close